


# APPLICATIONS

## Tamsulosin Hydrochloride and Related Substances

Ph. Eur. monograph 2131

### Overview

The Ph. Eur. Monograph 2131 outlines the separation of Tamsulosin from impurities. This method was studied and improvements were made to provide faster separations within allowable adjustments.



### Ph. Eur. Monograph 2131 Details- Tamsulosin (A)

<b>Reference Solution</b>	<b>(b)</b> Dissolve 4 mg of Tamsulosin Impurity D CRS* and 4 mg Tamsulosin Hydrochloride CRS* in the mobile phase and dilute to 20.0 mL with the mobile phase. Dilute 2.0 mL of this solution to 20.0 mL with the mobile phase.
	<b>(c)</b> Dissolve 4 mg of Tamsulosin Impurity H CRS* and 4 mg Tamsulosin Hydrochloride CRS* in the mobile phase and dilute to 20.0 mL with the mobile phase. Dilute 2.0 mL of this solution to 20.0 mL with the mobile phase.

### Column

<b>Size</b>	150 x 4.6 mm
<b>Stationary Phase</b>	Octadecylsilyl silica gel for chromatography R (5 µm).
<b>Temperature</b>	40 °C
<b>Mobile Phase</b>	Dissolve 3.0 g of sodium hydroxide R in a mixture of 8.7 mL of perchloric acid R and 1.9 L of water R; adjust to pH 2.0 with 0.5 M sodium hydroxide and dilute to 2 L with water R; to 1.4 L of this solution, add 600 mL of acetonitrile R.
<b>Flow Rate</b>	1.3 mL/min
<b>Detection</b>	Spectrophotometer @ 225 nm
<b>Injection</b>	10 µL
<b>Run Time</b>	1.5 times the retention of Tamsulosin (about 6 min)

### System Suitability


<b>Reference Solution (b)</b>	Minimum resolution of 6.0 between peaks due to Impurity D and Tamsulosin
-------------------------------	--

\* Tamsulosin impurity D CRS\* (Y0000651), Tamsulosin Impurity H CRS (Y0000652) and Tamsulosin Hydrochloride CRS (Y0000650) were purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allée Kastner CS 30026F - 67081 STRASBOURG (France).

### Method 1

Original Method as Described in the Monograph

**Column:** Kinetex<sup>®</sup> Core-Shell C18 5 µm  
**Dimensions:** 150 x 4.6 mm  
**Part No.:** 00F-4601-E0  
**Flow Rate:** 1.3 mL/min  
**Sample:** 1. Impurity B  
           2. Tamsulosin  
**Elution Time of Last Peak:** 5.47 min  
**Rs Impurity D and Tamsulosin:** 11.78



### Adjustments for Meeting System Suitability

(European Pharmacopeia 9.0, Chapter 2.2.46. Chromatographic separation techniques)

Method Parameter	Allowed Adjustments (isocratic elution)	Method 1
<b>Mobile Phase pH</b>	± 0.2 units	2 (as specified)
<b>Concentration of Salts in Buffer</b>	± 10 %	As specified in Monograph 2131 Details Table
<b>Composition of the Mobile Phase</b>	± 30 % of the minor solvent component relative or 2 % absolute, whichever is the larger. No other component is altered by more than 10 % absolute.	As specified in Monograph 2131 Details Table
<b>Wavelength of Detector</b>	No deviations permitted	225 nm (as specified)
<b>Injection Volume</b>	May be decreased, provided detection and repeatability of the peak(s) to be determined are satisfactory.	10 µL (as specified)
<b>Column Temperature</b>	± 10 %	40 °C (as specified)
<b>Stationary Phase</b>	No change of the identity of the substituent permitted (e.g. no replacement of C8 by C18)	Octadecylsilyl silica gel for chromatography (as specified)
<b>Column Length</b>	± 70 %	150 mm (as specified)
<b>Column Internal Diameter</b>	± 25 %	4.6 mm (as specified)
<b>Particle Size</b>	-50 %	5 µm (as specified)
<b>Flow Rate</b>	± 50 %	1.3 mL/min (as specified)

# APPLICATIONS

## Ph. Eur. Monograph 2131 Details- Tamsulosin (B)

**Reference Solution** (c) Dissolve 4 mg of Tamsulosin Impurity H CRS\* and 4 mg Tamsulosin Hydrochloride CRS\* in the mobile phase and dilute to 20.0 mL with the mobile phase. Dilute 2.0 mL of this solution to 20.0 mL with the mobile phase.

### Column

<b>Size</b>	150 x 4.6 mm
<b>Stationary Phase</b>	Octadecylsilyl silica gel for chromatography R (5 µm).
<b>Temperature</b>	40 °C
<b>Mobile Phase</b>	Dissolve 3.0 g of sodium hydroxide R in a mixture of 8.7 mL of perchloric acid R and 1.9 L of water R; adjust to pH 2.0 with 0.5 M sodium hydroxide and dilute to 2 L with water R; add 2 L of acetonitrile R.
<b>Flow Rate</b>	1.0 mL/min
<b>Detection</b>	Spectrophotometer @ 225 nm
<b>Injection</b>	10 µL
<b>Run Time</b>	5 times the retention of Tamsulosin (about 2.5 min)

### System Suitability


**Reference Solution (c)** Minimum resolution of 2.0 between peaks due to Tamsulosin and Impurity H

\* Tamsulosin Impurity D CRS\* (Y0000651), Tamsulosin Impurity H CRS (Y0000652) and Tamsulosin Hydrochloride CRS (Y0000650) were purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allee Kastner CS 30026F - 67081 STRASBOURG (France).

### Method 1

Original Method as Described in the Monograph

**Column:** Kinetex<sup>®</sup> Core-Shell C18 5 µm  
**Dimensions:** 150 x 4.6 mm  
**Part No.:** 00F-4601-E0  
**Flow Rate:** 1.0 mL/min  
**Sample:** 1. Impurity D  
 2. Tamsulosin  
 3. Impurity H  
**Elution Time of Last Peak:** 3.01 min  
**Rs Tamsulosin and Impurity H:** 15.37



App ID 21489

### Method 1 Adjustments for Meeting System Suitability (European Pharmacopeia 9.0, Chapter 2.2.46. Chromatographic separation techniques)

Method Parameter	Allowed Adjustments (isocratic elution)	Method 1
<b>Mobile Phase pH</b>	± 0.2 units	2 (as specified)
<b>Concentration of Salts in Buffer</b>	± 10 %	As specified in Monograph 2131 Details Table
<b>Composition of the Mobile Phase</b>	± 30 % of the minor solvent component relative or 2 % absolute, whichever is the larger. No other component is altered by more than 10 % absolute.	As specified in Monograph 2131 Details Table
<b>Wavelength of Detector</b>	No deviations permitted	225 nm (as specified)
<b>Injection Volume</b>	May be decreased, provided detection and repeatability of the peak(s) to be determined are satisfactory.	10 µL (as specified)
<b>Column Temperature</b>	± 10 °C	40 °C (as specified)
<b>Stationary Phase</b>	No change of the identity of the substituent permitted (e.g. no replacement of C18 by C8)	Octadecylsilyl silica gel for chromatography
<b>Column Length</b>	± 70 %	150 mm (as specified)
<b>Column Internal Diameter</b>	± 25 %	4.6 mm (as specified)
<b>Particle Size</b>	-50 %	5 µm (as specified)
<b>Flow Rate</b>	± 50 %	1.0 mL/min (as specified)

# APPLICATIONS

## Kinetex® Ordering Information

5 µm Minibore Columns (mm)					SecurityGuard™ ULTRA Cartridges <sup>†</sup>
Phases	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
C18	00A-4601-AN	00B-4601-AN	00D-4601-AN	00F-4601-AN	AJ0-8782 for 2.1 mm ID

5 µm MidBore™ Columns (mm)				SecurityGuard ULTRA Cartridges <sup>†</sup>
Phases	50 x 3.0	100 x 3.0	150 x 3.0	3/pk
C18	00B-4601-Y0	00D-4601-Y0	00F-4601-Y0	AJ0-8775 for 3.0 mm ID

5 µm Analytical Columns (mm)					SecurityGuard ULTRA Cartridges <sup>†</sup>
Phases	50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	3/pk
C18	00B-4601-E0	00D-4601-E0	00F-4601-E0	00G-4601-E0	AJ0-8768 for 4.6 mm ID

5 µm Semi-Preparative Columns (mm)			SecurityGuard SemiPrep Cartridges <sup>***</sup>
Phases	150 x 10	250 x 10	3/pk
C18	00F-4601-N0	00G-4601-N0	AJ0-9278 for 9-16 mm ID

<sup>†</sup>SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000

<sup>\*\*\*</sup>SemiPrep SecurityGuard Cartridges require holder, Part No.: AJ0-9281



# APPLICATIONS

## Australia

t: +61 (0)2-9428-6444  
f: +61 (0)2-9428-6445  
auinfo@phenomenex.com

## Austria

t: +43 (0)1-319-1301  
f: +43 (0)1-319-1300  
anfrage@phenomenex.com

## Belgium

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
f: +31 (0)30-2383749  
beinfo@phenomenex.com

## Canada

t: +1 (800) 543-3681  
f: +1 (310) 328-7768  
info@phenomenex.com

## China

t: +86 400-606-8099  
f: +86 (0)22 2532-1033  
phen@agela.com

## Denmark

t: +45 4824 8048  
f: +45 4810 6265  
nordicinfo@phenomenex.com

## Finland

t: +358 (0)9 4789 0063  
f: +45 4810 6265  
nordicinfo@phenomenex.com

## France

t: +33 (0)1 30 09 21 10  
f: +33 (0)1 30 09 21 11  
franceinfo@phenomenex.com

## Germany

t: +49 (0)6021-58830-0  
f: +49 (0)6021-58830-11  
anfrage@phenomenex.com

## India

t: +91 (0)40-3012 2400  
f: +91 (0)40-3012 2411  
indiainfo@phenomenex.com

## Ireland

t: +353 (0)1 247 5405  
f: +44 1625-501796  
eireinfo@phenomenex.com

## Italy

t: +39 051 6327511  
f: +39 051 6327555  
italiainfo@phenomenex.com

## Luxembourg

t: +31 (0)30-2418700  
f: +31 (0)30-2383749  
nlinfo@phenomenex.com

## Mexico

t: 01-800-844-5226  
f: 001-310-328-7768  
tecnicomx@phenomenex.com

## The Netherlands

t: +31 (0)30-2418700  
f: +31 (0)30-2383749  
nlinfo@phenomenex.com

## New Zealand

t: +64 (0)9-4780951  
f: +64 (0)9-4780952  
nzinfo@phenomenex.com

## Norway

t: +47 810 02 005  
f: +45 4810 6265  
nordicinfo@phenomenex.com

## Puerto Rico

t: +1 (800) 541-HPLC  
f: +1 (310) 328-7768  
info@phenomenex.com

## Spain

t: +34 91-413-8613  
f: +34 91-413-2290  
espinfo@phenomenex.com

## Sweden

t: +46 (0)8 611 6950  
f: +45 4810 6265  
nordicinfo@phenomenex.com

## United Kingdom

t: +44 (0)1625-501367  
f: +44 (0)1625-501796  
ukinfo@phenomenex.com

## USA

t: +1 (310) 212-0555  
f: +1 (310) 328-7768  
info@phenomenex.com

## All other countries Corporate Office USA

t: +1 (310) 212-0555  
f: +1 (310) 328-7768  
info@phenomenex.com